GLP-1 RAs demonstrated effectiveness and safety for managing hypothalamic obesity in craniopharyngioma patients, addressing a condition with almost no effective treatments.
Hope for the hopelessCraniopharyngioma obesity had no effective treatment. GLP-1 drugs provide the first meaningful option for these rare patients
What the researchers found
GLP-1 RAs: effective and safe for hypothalamic obesity in craniopharyngioma patients, addressing a condition with essentially no prior effective treatments.
Why it matters
Craniopharyngioma obesity devastates quality of life with no effective treatment. GLP-1 drugs could be transformative for these patients.
How the study worked
Study evaluating GLP-1 RA effectiveness and safety in craniopharyngioma patients with hypothalamic obesity.
What this study cannot tell us
Rare condition limits sample sizes.
How to read the evidence
Study in rare population.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs work even when the brain's appetite center is damaged — demonstrating non-hypothalamic mechanisms of action.
Questions still open
- How do GLP-1 drugs work when the hypothalamus is damaged?
- Should all craniopharyngioma patients receive GLP-1 drugs?
- Would tirzepatide provide even greater benefit?
Common questions
What is craniopharyngioma obesity?
Can GLP-1 drugs help when the brain's appetite center is damaged?
Read the original research
Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.
Diabetes, obesity & metabolism, 28(1), 443-451
Citation
Lambert, Flora; Guillon, Emilie; Gatta-Cherifi, Blandine; Soula, Hedi; Poitou, Christine; Faucher, Pauline. (2026). Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.. Diabetes, obesity & metabolism, 28(1), 443-451. https://doi.org/10.1111/dom.70216